Emcure Pharmaceuticals’ arm inks in-licensing agreement with WiQo

02 Apr 2025 Evaluate

Emcure Pharmaceuticals’ a wholly owned subsidiary -- Emcutix Biopharmaceuticals has signed exclusive in-licensing agreement with WiQo. The strategic partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region. 

PRX-PLUS has a unique product feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience. Over 40,000 dermatologists and aesthetic doctors worldwide use WiQo’s patented formulas. Since 2011 over 8 million needle-free skin booster professional procedures have been performed globally. 

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Emcure Pharma Share Price

1070.85 -11.45 (-1.06%)
22-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1747.25
Dr. Reddys Lab 1174.85
Cipla 1528.10
Lupin 2046.90
Zydus Lifesciences 852.50
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...